Introduction
Since their appearance in the 1980s, selective serotonin reuptake inhibitors (SSRIs) have been widely prescribed to treat depression. Although they are usually well tolerated, it has been hypothesized that in certain cases, especially in young patients or during the first weeks of treatment, they could increase the risk of suicide.
One of the most debated explanations is that SSRIs reduce apathy and increase energy before improving affective symptoms such as hopelessness or suicidal ideation. This temporary imbalance could, paradoxically, facilitate acting on suicidal impulses in patients who previously lacked the drive to do so.
Scientific Evidence: What Do Studies Say?
1. BMJ Systematic Review (Fergusson et al., 2005)
In a meta-analysis published in the British Medical Journal, Fergusson and colleagues analyzed 702 clinical trials and found that the risk of suicide attempts was twice as high in patients who received SSRIs compared to placebo.
Although the authors warned that such events were rare, the magnitude of the risk was statistically significant.
"The absolute difference was 5.6 additional suicide attempts per 1000 patients treated."
This finding was particularly concerning because the studies included were randomized clinical trials, which reduces bias.
2. David Healy’s BMJ Editorial (2006)
David Healy, psychiatrist and critic of the pharmaceutical industry, noted that SSRIs can not only induce suicidal ideation, but also phenomena such as akathisia (psychomotor restlessness), which has been associated with increased suicide risk.
Healy argues that many clinical trials filter or reinterpret data on self-harm, masking the true impact of these medications on some patients.
"In some trials, suicide attempts were reclassified as symptoms of the underlying illness."
3. Apathy as a Side Effect? (Acta Neuropsychiatrica)
A review article in Acta Neuropsychiatrica describes antidepressant-induced apathy as a relatively common side effect, with a prevalence of up to 46%.
Apathy manifests as:
- Loss of motivation
- Decreased interest
- Flat emotional affect
When this state is reversed through treatment, psychomotor activation may occur without accompanying affective improvement.
4. Akathisia and Impulsivity (British Journal of Psychiatry)
Michael Peet (1994) described the emergence of hypomania or impulsivity in patients treated with SSRIs. Although these cases are less frequent, their existence supports the hypothesis that changes in mood and activity may occur out of sync, creating a “risk window” for suicidal behaviors.
5. Review on Global Impact (Neuropsychiatric Disease and Treatment, 2020)
A recent review analyzed data from multiple studies and concluded that:
- Suicide risk does not increase significantly in older adults
- In adolescents and young adults, the risk is real and clinically relevant
- The highest risk is concentrated in the first 4 weeks of treatment
"Risk must be contextualized based on the patient’s age and medical history. It is not about avoiding SSRIs, but about knowing when and how to use them."
What Do Health Authorities Recommend?
Based on these data, organizations such as the FDA (U.S.) and EMA (European Union) have issued clear warnings:
Implemented Safety Measures
🚨 “Black Box” Label
Mandatory warning for all antidepressants in patients under 25 (FDA, 2004).
🔍 Strict Monitoring
- Frequent psychiatric review during the first 2–4 weeks
- Specialized follow-up for at-risk populations
👨👩👧👦 Family Education
- Training for family members and caregivers
- Identification of signs of worsening
- Detection of behavioral changes
⚖️ Risk–Benefit Assessment
- Personalized analysis before prescribing
- Consideration of non-pharmacological alternatives
- Dose and timing adjustments depending on the patient’s profile
The Activation Hypothesis: Proposed Mechanism
How Does It Work?
- Initial phase (Weeks 1–2): The SSRI increases energy and reduces apathy
- Temporal mismatch: Depressive symptoms (hopelessness, suicidal ideation) persist
- Risk window: The patient now has the energy to act on preexisting suicidal impulses
Additional Risk Factors
- Young age (under 25)
- Family history of suicide
- Comorbid disorders (anxiety, bipolar disorder)
- Substance abuse
- Recent stressful life events
Practical Clinical Implications
For the Prescribing Physician
✅ Conduct a thorough suicide risk assessment before prescribing
✅ Inform the patient and family about possible paradoxical effects
✅ Schedule frequent follow-ups in the first weeks
✅ Consider non-pharmacological therapies as first-line options in mild cases
For the Patient and Family
🔴 Be alert to sudden changes in behavior
🔴 Do not discontinue medication without medical supervision
🔴 Report any worsening immediately
🔴 Have a crisis plan in place
Conclusion
Antidepressants are fundamental tools in managing affective disorders, but they are not free from paradoxical effects. The so-called apathy and activation hypothesis suggests that SSRIs may, in some cases, increase the risk of suicide in early phases of treatment by releasing energy before emotional suffering has improved.
A Balanced Approach
Far from delegitimizing their use, this knowledge should promote:
- More personalized prescribing
- Close monitoring during the first weeks
- Ongoing dialogue between patient and clinician
- Consideration of the patient’s psychosocial context
It is not enough to treat the chemistry; one must also care for the patient’s context and emotional narrative.
Evidence-based medicine teaches us that all treatments have risks. What matters is knowing them, evaluating them, and managing them appropriately to maximize benefits and minimize harm.
Bibliographic References
Fergusson, D., Doucette, S., Glass, K. C., Shapiro, S., Healy, D., Hebert, P., & Hutton, B. (2005). Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ, 330(7488), 396. https://doi.org/10.1136/bmj.330.7488.396
Healy, D. (2006). Did regulators fail over selective serotonin reuptake inhibitors? BMJ, 333(7558), 92–95. https://doi.org/10.1136/bmj.333.7558.92
Peet, M. (1994). Induction of hypomania and mania by selective serotonin reuptake inhibitors. British Journal of Psychiatry, 164(4), 549–550. https://doi.org/10.1192/bjp.164.4.549
Wongpakaran, N., & Wongpakaran, T. (2020). The impact of antidepressants on suicidality in major depression: An overview of systematic reviews. Neuropsychiatric Disease and Treatment, 16, 355–362. https://doi.org/10.2147/NDT.S229310
Price, J., & Rosenberg, J. (2005). Adverse effects of antidepressants: A concern for the whole age spectrum. Drug Safety, 28(2), 113–122. https://doi.org/10.2165/00002018-200528020-00003